Reported Sunday, Lilly Brings Updated Phase 3 Selpercatinib Data Versus Cabozantinib Or Vandetanib In RET-Mutant Medullary Thyroid Cancer To ESMO 2026, Alongside Sofetabart Mipitecan, Olomorasib And Abemaciclib Presentations

뉴스 본문을 불러오고 있어요.

Reported Sunday, Lilly Brings Updated Phase 3 Selpercatinib Data Versus Cabozantinib Or Vandetanib In RET-Mutant Medullary Thyroid Cancer To ESMO 2026, Alongside Sofetabart Mipitecan, Olomorasib And Abemaciclib Presentations | 웨이프 WAPE

Reported Sunday, Lilly Brings Updated Phase 3 Selpercatinib Data Versus Cabozantinib Or Vandetanib In RET-Mutant Medullary Thyroid Cancer To ESMO 2026, Alongside Sofetabart Mipitecan, Olomorasib And Abemaciclib Presentations

기사 요약

관련 종목

댓글 —